US FDA clearance for its ground-breaking chest X-ray AI Solution secured by DeepTek.ai 

• ByStartupStory     |    October 27, 2023

DeepTek.ai, a prominent medical imaging Artificial Intelligence (AI) company in India, has announced that it has obtained clearance from the US Food and Drug Administration (FDA) for its innovative chest X-ray AI solution, known as the CXR Analyzer. This cutting-edge technology employs deep learning algorithms to identify anomalies in chest X-rays, automatically detecting, categorizing, and highlighting suspicious areas to assist clinicians in making precise interpretations.

Unlike traditional point AI solutions designed to identify specific pathologies, DeepTek’s chest X-ray AI covers the entire chest area, providing analysis for a broader range of lung, pleural, and cardiac pathologies, as well as foreign bodies and hardware on the chest. It is compatible with various types of X-ray machines, including those used in hospitals, mobile units, portable units, hand-held devices, and ultra-portable units, making it versatile and powerful.

This AI model accelerates decision-making by detecting and pinpointing suspicious lesions in chest X-rays, which are crucial for diagnosing conditions such as lung infections, cancer, and chronic lung diseases. In a world where 3.5 billion X-rays are conducted annually, 1.5 billion of which are chest X-rays, the need for accurate interpretation is essential. The shortage of radiologists further underscores the role of AI in addressing this challenge.

Dr. Amit Kharat, Co-Founder of DeepTek.ai, stated, “DeepTek CXR Analyzer v1.0 is a game-changer, reducing a radiologist’s workload by an impressive 30-50%. With FDA clearance, we’re not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we’re unlocking a world of possibilities for improved outcomes across various medical specialities.”

“The radiology AI market is growing at around 34% CAGR and is anticipated to reach approximately $30 billion by 2030. Our entire product suite is now cleared by the US FDA, and coupled with the marquee customers we have successfully established, this positions us as a leader in this space,” added Ajit Patil, Co-Founder of DeepTek.ai.

DeepTek’s AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers use DeepTek’s AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened for tuberculosis using DeepTek’s chest X-Ray Analyzer. In Singapore, DeepTek’s US FDA-approved platform, Augmento, has been deployed as the national radiology AI platform, enhancing productivity and the quality of care in public hospitals.

Exciting news! We’re now on WhatsApp Channels too.  Subscribe today by clicking the link and stay updated with the latest insights in the startup ecosystem! Click here!

With its operations based in Pune, DeepTek has approximately 200 team members and collaborates with partners such as TATA Capital and NTT DATA Japan.

Follow Startup Story